Beihai Biotech Secures FDA IND Approval for First‑In‑Class Peptide‑Drug Conjugate BH1621
China‑based Zhuhai Beihai Biotech Co., Ltd. announced today that its Category 1 innovative drug BH1621 has...
Sichuan Biokin’s SystImmune Receives $250 Million Triggered by Phase 2/3 Milestone in EGFR×HER3 ADC
China‑based Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its wholly‑owned subsidiary SystImmune, Inc....
Boehringer Ingelheim Secures FDA Approval for Nerandomilast (JASCAYD) in Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim (BI) announced today that the U.S. Food and Drug Administration (FDA) has approved...
China’s NMPA Approves Mufemilast (Hemay005) — Hemei’s First Domestic PDE4 Inhibitor
The National Medical Products Administration (NMPA) announced that Jiangxi Hemei Pharmaceutical Co., Ltd. has received...
State Council Introduces 2026 Regulations Governing Clinical Research of Biomedical New Technologies in China
The Chinese State Council has issued the Regulations on the Administration of Clinical Research and...
BMS Acquires Orbital for $1.5 B in RNA‑Based Immunotherapy Deal
Bristol-Myers Squibb (BMS, NYSE: BMY) announced today that it will acquire Orbital Therapeutics (“Orbital”), a...
Peijia Medical Secures NMPA Approval for GeminiOne TEER System
Peijia Medical Limited (HKG: 9996) announced today that the National Medical Products Administration (NMPA) of...
PegBio Signs Non‑Binding Term Sheet with UAE‑Based PDC for Exclusive Middle East & Africa License of Visepegenatide
PegBio Co., Ltd. (HKG: 2565) announced today that it has entered into a non‑binding term...
Tigermed Completes Share Transfer of Teddy Clinical Laboratory to Frontage Laboratories for RMB 270 Million
China‑based Hangzhou Tigermed Consulting Co., Ltd. (HKG: 3347) announced that it and its subsidiary Jiaxing...
BeOne Medicines Terminates Patent Dispute with AbbVie’s Pharmacyclics Over BTK Inhibitors
BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced today that it has terminated...
National Drug Alliance Moves VBP 11th‑Round Information Disclosure Conference to 27 Oct 2025 in Shanghai
The National Drug Alliance Procurement Office announced a schedule change for the 11th round of...
Novo Nordisk to Acquire Akero Therapeutics for $5.2 Billion, Secures Future Value with Efruxifermin
Novo Nordisk A/S (NYSE: NVO) announced today that it will acquire Akero Therapeutics (NASDAQ: AKRO) for...
Xingqi Pharma Secures NMPA Approval for SQ‑129, a Novel Treatment for Diabetic Macular Edema
China‑based Shenyang Xingqi Pharmaceutical Co., Ltd. (SHE: 300573) announced today that the China National Medical...
Shanghai Henlius Biotech Achieves Primary Endpoint in Phase 3 Trial of Serplulimab for Early‑Stage Gastric Cancer
Shanghai Henlius Biotech Inc. (HKG: 2696) today announced that its phase 3, randomized, double‑blind, multi‑center study...
JW (Cayman) Therapeutics Secures NMPA Acceptance for Carteyva, Introducing In‑House Lentiviral Vector Production
JW (Cayman) Therapeutics Co. Ltd (HKG: 2126) announced today that the National Medical Products Administration...
Acotec Scientific Receives FDA 510(k) Clearance for Endovenous Radiofrequency Ablation System
Acotec Scientific Holdings Limited (HKG: 6669) announced on October 7, 2025 that its Endovenous Radiofrequency Ablation System...
Beijing Luzhu Biotechnology Completes U.S. Phase 1 Trial of LZ901, Demonstrating Strong Safety and Immunogenicity
Beijing Luzhu Biotechnology Co., Ltd. (HKG: 2480) announced today that its Phase 1 clinical trial of...
Huadong Medicine Secures NMPA Trial Approval for HDM2017, a CDH17‑Targeting ADC
China‑based Huadong Medicine Co., Ltd. (SHE: 000963) announced that its novel antibody‑drug conjugate (ADC), HDM2017...
Chance Pharma Secures Exclusive China Deal with Huadong Medicine for CXG87 Inhaler
Hangzhou‑based Chance Pharmaceuticals Co., Ltd. has inked an exclusive commercialization agreement with Shanghai‑listed Huadong Medicine...
Takeda Shuts Down Cell‑Therapy Program, Eyes External Collaboration for γδ T‑Cell Platform
Takeda Pharmaceutical Co., Ltd. (TYO: 4502, NYSE: TAK) announced today that it is discontinuing all...